Martina Valgiusti

Meldola, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.

Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.

Journal: ESMO open

Published: April 12, 2025

Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation.

Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation.

Journal: Cell death & disease

Published: August 05, 2024

Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial.

Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial.

Journal: JCO precision oncology

Published: January 31, 2024

Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.

Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.

Journal: Therapeutic advances in medical oncology

Published: June 05, 2023

Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value.

Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value.

Journal: Molecular therapy. Methods & clinical development

Published: October 19, 2022

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.

Journal: Journal of personalized medicine

Published: September 29, 2022

Recurrent pneumothorax in a patient with liposarcoma as either a complication of lung micrometastasis or a potential adverse event from antibiotic therapy: A case report.

Recurrent pneumothorax in a patient with liposarcoma as either a complication of lung micrometastasis or a potential adverse event from antibiotic therapy: A case report.

Journal: Oncology letters

Published: February 09, 2022

Conversion Surgery in Gastric Cancer Carcinomatosis.

Conversion Surgery in Gastric Cancer Carcinomatosis.

Journal: Frontiers in oncology

Published: January 11, 2022

CNA Profiling of Single CTCs in Locally Advanced Esophageal Cancer Patients during Therapy Highlights Unexplored Molecular Pathways.

CNA Profiling of Single CTCs in Locally Advanced Esophageal Cancer Patients during Therapy Highlights Unexplored Molecular Pathways.

Journal: Cancers

Published: November 22, 2021

Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.

Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 29, 2021

Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies.

Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies.

Journal: Biomolecules

Published: June 30, 2021

Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.

Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.

Journal: Targeted oncology

Published: March 19, 2021

Showing 1-12 of 55

Last Updated: 09/26/2026